“We are now moving to broaden the launches, which gives us confidence that growth will accelerate, including growing faster than the market by the exit of this year.”

In context

“n upgrade to the first generations. We are seeing that with Volt. The conscious sedation aspect of Volt is extremely valuable in the U.S. and internationally, and it is specific to Volt by design. At the European Heart Rhythm meeting last week, albeit preliminary and small, we saw data suggesting the lesions that Volt creates are more durable. That balances the discussion on the EP market to be not only about efficiency and speed—because there are many patients to treat—but also better outcomes. We believe Volt can deliver speed and efficiency and better outcomes. The TactiFlex Duo feedback is very positive as well—easy to use, very fast lesion creation. This is on the TactiFlex chassis, so there is a lot of experience with that catheter, and there is a seamless switch between RF and PFA. We are now moving to broaden the launches, which gives us confidence that growth will accelerate, including growing faster than the market by the exit of this year. On market growth, there is debate—is it 15% or 20%? We think the market will be mid- to high-teens, and we are aiming to do better than that. The near-term outlook for the business looks really strong. More importantly, I like our long-term position. We have two new PFA catheters, a new ICE catheter, a new introducer, and we are constantly making annual upgrades to our mapping system. We have mapping infrastructure in place with clinical specialists—highly valuable to our customers. We will add a second-generation LAA device to this group. No company in this space has the kind of portfolio, completeness, experience, and field teams that we have. While not all of these products fall into EP as a reportable segment, many EPs also use our devices—pacemakers, ICDs—and our leadless technology”